UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September 2025
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Purple Biotech
On September 10, 2025, Purple Biotech Ltd. (the “Company”
or the “Registrant”) issued a press release “Purple Biotech Receives Intention to Grant a European Patent
Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance”, which is attached hereto
as Exhibit 99.1.
| Exhibit |
|
|
| 99.1 |
|
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| September 10, 2025 |
PURPLE BIOTECH LTD. |
| |
|
| |
By: |
/s/ Gil Efron |
| |
|
Gil Efron |
| |
|
Chief Executive Officer |
